Cost-effectiveness of chronic kidney disease mass screening test in Japan

Clinical and Experimental Nephrology

Volumn 16, Issue 2, 2012, Pages 279-291

  Kondo, Masahide ^a   Yamagata, Kunihiro ^a   Hoshi, Shu Ling ^a   Saito, Chie ^a   Asahi, Koichi ^b   Moriyama, Toshiki ^c   Tsuruya, Kazuhiko ^d   Yoshida, Hideaki ^e   Iseki, Kunitoshi ^f   Watanabe, Tsuyoshi ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

Chronic kidney disease; Cost effectiveness; Dipstick test; Mass screening; Proteinuria; Serum creatinine

Indexed keywords

CREATININE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DECISION TREE; DIAGNOSTIC TEST; DIPSTICK TEST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE POLICY; HIDDEN MARKOV MODEL; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL EXAMINATION; PROBABILITY; PROTEINURIA;

ADULT; COST-BENEFIT ANALYSIS; CREATININE; DECISION TREES; HUMANS; JAPAN; MASS SCREENING; PROTEINURIA; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84863717822     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0567-1     Document Type: Article

References (48)

1. Meguid El, Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331-440.
2. Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53:522-35.
3. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int. 2010;80:17-28.
4. Kiberd B. Screening for chronic kidney disease. BMJ. 2010;341:c5734.
5. de Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol. 2008;3:616-23.
6. Collins AJ, Vassalotti JA, Wang C, Li S, Gilbertson DT, Liu J, et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease. Am J Kidney Dis. 2009;53:S71-7.
7. Chen N, Hsu CC, Yamagata K, Langham R. Challenging chronic kidney disease: experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and Australia. Nephrology (Carlton). 2010;15:31-6.
8. Imai E, Yamagata K, Iseki K, Iso H, Horio M, Mkino H, et al. Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol. 2007;2:1360-6.
9. Kohro T, Furui Y, Mitsutake N, Fujii R, Morita H, Oku S, et al. The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. Int Heart J. 2008;49:193-203.
10. Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1-8.
11. Iseki K. Role of urinalysis in the diagnosis of chronic kidney disease (CKD). JMAJ. 2011;54:27-30.
12. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA. 2003;290:3101-14.
13. Ministry of Health, Labour and Welfare. Heisei 20 nendo tokutei kenko shinsatokutei hoken shidono jisshi jyokyo ni tsuite. Tokyo: Ministry of Health, Labour and Welfare; 2010.
14. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-To-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305:1545-52.
15. AkamaY Y, Kikuchi S, Sato K, Okada T, Yamaguchi T. Shokuiki teiki kenko shindan ni okeru seimitsu kensa jushin jyokyo-dai chukibo jigyojyo to shokibo jigyojyo no hikaku. Sangyoeiseigaku Zasshi. 2006;48:S60-1.
16. Tsuda K, Tsutsumi A, Kawakami N. Work-related factors associated with visiting a doctor for a medical diagnosis after a worksite screening for diabetes mellitus in Japanese male employees. J Occup Health. 2004;46:374-81.
17. Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2009. Tokyo: Tokyo Igakusha; 2009.
18. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800-5.
19. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305:1553-9.
20. Omae K, Ogawa T, Nitta K. Therapeutic advantage of angiotensin- converting enzyme inhibitors in patients with proteinuric chronic kidney disease. Heart Vessels. 2010;25:203-8.
21. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of 31 December , 2005. Tokyo: Japanese Society for Dialysis Therapy; 2006.
22. Kimura Y, Takishita S, Muratani H, Kinjo K, Shinzato Y, Muratani A, et al. Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med. 1998;37:736-45.
23. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med. 2003;163:361-6.
24. Fukiyama K, Kimura Y, Wakugami K, Muratani H. Incidence and long-Term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. Hypertens Res. 2000;23:127-35.
25. Suzuki K. Stroke register in Akita: incidence and the burden of diseases. Nippon Ronen Igakkai Zasshi. 2008;45:169-71.
26. Suzuki K. Chiiki nosocchu hassho toroku wo riyo shita nosocchu iryo no shitu no hyoka ni kansuru kenkyu: Heisei 15 nendo-17 nendo sogo kenkyu hokokusho. Report of Health and Labour Sciences Research Grants (Contract No.: H16-KENKO-014). Tokyo: Ministry of Health, Labour, and Welfare; 2006.
27. Iseki K, Wakugami K, Maehara A, Tozawa M, Muratani H, Fukiyama K. Evidence for high incidence of end-stage renal disease in patients after stroke and acute myocardial infarction at age 60 or younger. Am J Kidney Dis. 2001;38:1235-9.
28. Ministry of Health, Labour and Welfare. Vital statistics of Japan 2008. Tokyo: Health and Welfare Statistics Association; 2010.
29. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
30. Gold RM, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
31. Tajima R, Kondo M, Kai H, Saito C, Okada M, Takahashi H, et al. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol. 2010;14:340-8.
32. Saito I, Kobayashi M, Matsushita Y, Mori A, Kawasugi K, Saruta T. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res. 2008;31:1373-83.
33. Fukuhara S, Yamazaki C, Hayashino Y, Higashi T, Eichleay MA, Akiba T, et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ. 2007;7:217-31.
34. Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, et al. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med. 2007;46:157-62.
35. Seino Y. New diagnostic criteria for diabetes in Japan. Nippon Rinsho. 2010;68:2357-61.
36. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-28.
37. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-To-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422-37.
38. Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis. 2009;52:184-95.
39. Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ. 2010;341:5869.
40. Menon D, Stafinski T. Health technology assessment in Canada: 20 years strong? Value Health. 2009;12:S14-9.
41. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-28.
42. GISEN The Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-63.
43. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359-64.
44. Schmieder RE, Ruilope LM, Barnett AH. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol. 2011;24:569-80.
45. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736-43.
46. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.
47. Yamagata K, Makino H, Akizawa T, Iseki K, Itoh S, Kimura K, et al. Design and methods of a strategic outcome study for chronic kidney disease: frontier of renal outcome modifications in Japan. Clin Exp Nephrol. 2010;14:144-51.
48. Holland W. Screening for disease-consideration for policy. Euro Observer. 2006;8:1-4.